Table I.
The antitumor activity of fluoropyrimidines against human colon cancer xenografts in mice.
| IR (%) | ||||
|---|---|---|---|---|
|
|
||||
| Cell line | UFT alone 20 mg/kg/day |
UFT/LV 20/10 mg/kg/day |
Capecitabine 450 mg/kg/day |
|
| Colo 205 | 66.7 | 73.2 | b | 69.4 |
| WiDr | 59.3 | 71.9 | b | 48.2 |
| Colo 201 | 48.8 | 61.5 | b | 48.6 |
| KM12C | 54.5 | 78.8 | b | 57.8 |
| Col-1 | 49.1 | 68.2 | b | 30.3 |
| HCT-15 | 50.5 | 59.8 | a | 68.4 |
| DLD-1 | 48.8 | 56.2 | n.s. | 28.0 |
| LoVo | 51.5 | 61.0 | b | 77.6 |
| Colo 320DM | 52.3 | 60.3 | a | 35.0 |
| Co-3 | 47.1 | 62.2 | b | 33.1 |
| KM12C/FU | 22.8 | 55.1 | b | 17.7 |
The drugs were orally administered once daily for 14 consecutive days. On day 15, the inhibition ratio (IR) of each drug was evaluated. Each value is the mean IR of 6 mice tested.
a,b
Significantly different from the UFT 20 mg/kg/day group at p<0.05 and p<0.01 (Student’s t-test), respectively;
n.s, not significant.